GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status:
Enrolling by invitation
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This study intends to use Obinutuzumab, Zanubrutinib, and Lenalidomide sequential CD19/CD22
CAR-T in the treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma patients. The
main purpose of this study is to explore a new treatment mode for R/R B-NHL patients and
observe the efficacy and safety of this treatment regimen.
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University